Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definity-enhanced ultrasound for prostate cancer diagnosis
NCT05336786Phase 3Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Drug Delivery Systems
- Countries
- 2
01
Overview
A Phase 3 trial of perflutren lipid microspheres in prostate cancer (PCa), sponsored by Thomas Jefferson University. Started Jun 2022; status: active, not recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05336786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336786.